Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 14/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | DOCK5 | Q9H7D0 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12654100 | 1.00 | LIPE (0.36) | LIPEHRH3DOCK5METAP2 | |
| SCHEMBL1651068 | 1.00 | LIPE (0.36) | LIPEHRH3DOCK5METAP2 | |
| SCHEMBL1650437 | 1.00 | LIPE (0.36) | LIPEHRH3DOCK5METAP2 | |
| Hydrochloric Acid SCHEMBL1650694 | 0.99 | LIPE (0.36) | LIPEHRH3DOCK5METAP2 | |
| Hydrochloric Acid SCHEMBL1650695 | 0.99 | LIPE (0.36) | LIPEHRH3DOCK5METAP2 | |
| SCHEMBL15416964 | 0.89 | LIPE (0.41) | LIPE | |
| SCHEMBL1650708 | 0.88 | DOCK5 (0.48) | LIPEHRH3DOCK5METAP2 | |
| SCHEMBL1650705 | 0.88 | DOCK5 (0.48) | LIPEHRH3DOCK5METAP2 | |
| SCHEMBL15416974 | 0.88 | DOCK5 (0.48) | LIPEHRH3DOCK5METAP2 | |
| SCHEMBL12076166 | 0.87 | LIPE (0.43) | LIPEHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359297-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2016-06-07 | — | — | US | claimed |
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | US | claimed |
| EP-2493304-B1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | claimed |
| US-8633190-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-01-21 | — | — | US | claimed |
| EP-2493304-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2012-09-05 | — | — | EP | claimed |
| US-9359297-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2016-06-07 | — | — | US | disclosed |
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | US | disclosed |
| EP-2493304-B1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | disclosed |
| US-8633190-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-01-21 | — | — | US | disclosed |
| EP-2493304-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011053575-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | REN, AGTR1, PDE6D | LIPE 3322/4885HRH3 3454/4885DOCK5 2597/4885 |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | REN, AGTR1, PDE6D | LIPE 3322/4885HRH3 3454/4885DOCK5 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.